|
1
|
Amieva M and Peek RM Jr: Pathobiology of
Helicobacter pylori-induced gastric cancer.
Gastroenterology. 150:64–78. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guilford PJ: Markers for detection of
gastric cancer. US Patent US 9,310,370 B2. Filed May 14, 2010;
issued April 12. 2016.
|
|
3
|
Liang H: Intraperitoneal chemotherapy for
locally advanced gastric cancer to prevent and treat peritoneal
carcinomatosis. Transl Gastroenterol Hepatol. 1:622016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mikami J, Kimura Y, Makari Y, Sawada G,
Nakahira S, Nakata K, Yamamoto T, Tsujie M and Ohsato H: A case of
self-expandable metallic stent placement to treat colon obstruction
due to metastatic gastric cancer. Gan To Kagaku Ryoho.
43:1899–1901. 2016.(In Japanese). PubMed/NCBI
|
|
5
|
Ghosn M, Tabchi S, Kourie HR and Tehfe M:
Metastatic gastric cancer treatment: Second line and beyond. World
J Gastroenterol. 22:3069–3077. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hofmann F, Marconi LS, Stewart F, Lam TB,
Bex A, Canfield SE and Ljungberg B: Targeted therapy for metastatic
renal cell carcinoma (protocol). Cochrane Database Syst Rev.
9:CD0127962017.
|
|
7
|
Li J, Zhao X, Chen L, Guo H, Lv F, Jia K,
Yv K, Wang F, Li C, Qian J, et al: Safety and pharmacokinetics of
novel selective vascular endothelial growth factor receptor-2
inhibitor YN968D1 in patients with advanced malignancies. BMC
Cancer. 10:5292010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y,
Sun G, Yang Y, Wang L, Xu N, et al: Apatinib for
chemotherapy-refractory advanced metastatic gastric cancer: Results
from a randomized, placebo-controlled, parallel-arm, phase II
trial. J Clin Oncol. 31:3219–3225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shen Q, Ma X, Hu W, Chen L, Huang J and
Guo Y: Intensity-modulated radiotherapy versus three-dimensional
conformal radiotherapy for stage I–II natural killer/T-cell
lymphoma nasal type: Dosimetric and clinical results. Radiat Oncol.
8:1522013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang N, Yang J, Lu J, Qiao Q, Bao G, Wu T
and He X: IL-17 gene polymorphism is associated with susceptibility
to gastric cancer. Tumour Biol. 35:10025–10030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maniati E, Soper R and Hagemann T: Up for
mischief? IL-17/Th17 in the tumour microenvironment. Oncogene.
29:5653–5662. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nishiofuku H, Tanaka T, Sakaguchi H,
Yamamoto K, Inoue M, Sueyoshi S, Shinnkai T, Hasegawa M and
Kichikawa K: Hepatic arterial infusion chemotherapy combined with
venous embolization in a patient with hepatic metastases with an
arteriovenous shunt. Cardiovasc Intervent Radiol. 32:796–800. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thomas RM and Sobin LH: Gastrointestinal
cancer. Cancer. 75 (Suppl):154–170. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshida K, Yamaguchi K, Okumura N,
Tanahashi T and Kodera Y: Is conversion therapy possible in stage
IV gastric cancer: The proposal of new biological categories of
classification. Gastric Cancer. 19:329–338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hsu PI, Chen CH, Hsieh CS, Chang WC, Lai
KH, Lo GH, Hsu PN, Tsay FW, Chen YS, Hsiao M, et al:
Alpha1-antitrypsin precursor in gastric juice is a novel biomarker
for gastric cancer and ulcer. Clin Cancer Res. 13:876–883. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Carter GC, Kaltenboeck A, Ivanova J, Liepa
AM, San Roman A, Koh M, Rajan N, Cheng R, Birnbaum HG, Kim JS, et
al: Real-world treatment patterns among patients with advanced
gastric cancer in South Korea. Cancer Res Treat. 49:578–587. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roviello G, Ravelli A, Polom K, Petrioli
R, Marano L, Marrelli D, Roviello F and Generali D: Apatinib: A
novel receptor tyrosine kinase inhibitor for the treatment of
gastric cancer. Cancer Lett. 372:187–191. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang H: Apatinib for molecular targeted
therapy in tumor. Drug Des Devel Ther. 9:6075–6081. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O'Brien RL, Roark CL and Born WK:
IL-17-producing gammadelta T cells. Eur J Immunol. 39:662–666.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martin-Orozco N and Dong C: The
IL-17/IL-23 axis of inflammation in cancer: Friend or foe? Curr
Opin Investig Drugs. 10:543–549. 2009.PubMed/NCBI
|
|
21
|
Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma
L, Xue X, Wei G, Liu X and Fang G: The prevalence of Th17 cells in
patients with gastric cancer. Biochem Biophys Res Commun.
374:533–537. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma D, Zhu X, Zhao P, Zhao C, Li X, Zhu Y,
Li L, Sun J, Peng J, Ji C and Hou M: Profile of Th17 cytokines
(IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients
with immune thrombocytopenic purpura. Ann Hematol. 87:899–904.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Scott AJ, Messersmith WA and Jimeno A:
Apatinib: A promising oral antiangiogenic agent in the treatment of
multiple solid tumors. Drugs Today (Barc). 51:223–229. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Geng R and Li J: Apatinib for the
treatment of gastric cancer. Expert Opin Pharmacother. 16:117–122.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wainberg ZA, Anghel A, Desai AJ, Ayala R,
Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ and Finn RS:
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively
inhibits HER2-amplified human gastric cancer cells and is
synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res.
16:1509–1519. 2010. View Article : Google Scholar : PubMed/NCBI
|
